Radiation Combined With BIspecific T-Cell Engager in DLL3 Expressing Tumors
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
Clinical Trials Related to Medullary Thyroid Cancer
Related studies linked through entity extraction aliases.
Genetic Bases of Neuroendocrine Neoplasms in Mexican Patients
- Status
- RECRUITING
- Phase
- N/A
Predictive Factors for Medullary Thyroid Cancer Aggressiveness
- Status
- COMPLETED
- Phase
- N/A
68Ga-TCR-FAPI PET/CT Guided Precision Surgery for MTC
- Status
- RECRUITING
- Phase
- NA
Is Desmoplastic Stromal Reaction Useful to Modulate Lymph Node Dissection in Sporadic Medullary Thyroid Carcinoma?
- Status
- COMPLETED
- Phase
- N/A
Treatment of Advanced Endocrine Tumor With Iindividualized mRNA Neoantigen Vaccine (mRNA-0523-L001)
- Status
- RECRUITING
- Phase
- NA
A Detailed Look At What Patients Experience In Medullary Thyroid Cancer Clinical Study
- Status
- NOT_YET_RECRUITING
- Phase
- N/A
Study of Anlotinib in Patients With Advanced Medullary Thyroid Carcinoma
- Status
- RECRUITING
- Phase
- PHASE4
A Study of TY-1091 in Patients With Advanced Solid Tumors
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
Evaluation of the 18F-PSMA Positron Emission Tomography (PET)/CT in Patients With Medullary Thyroid Cancer
- Status
- COMPLETED
- Phase
- NA
Phase I/II Study of SY-5007, a RET Inhibitor, in Patients With RET-altered Advanced Solid Tumor
- Status
- UNKNOWN
- Phase
- PHASE1/PHASE2
A Study of Pralsetinib Versus Standard of Care (SOC) for Treatment of RET-Mutated Medullary Thyroid Cancer (MTC).
- Status
- WITHDRAWN
- Phase
- PHASE3
Amyloid Proteins From Medullary Thyroid Cancer and Laryngeal Amyloidosis
- Status
- NOT_YET_RECRUITING
- Phase
- N/A
Thermal Ablation of Cervical Metastases From Thyroid Carcinoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- NA
A Study of Selpercatinib (LY3527723) in Participants With Advanced Solid Tumors Including RET Fusion-positive Solid Tumors, Medullary Thyroid Cancer and Other Tumors With RET Activation
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
A Study of Selpercatinib (LY3527723) in Participants With RET-Mutant Medullary Thyroid Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
Pre-Approval Access Program (PAAP) for Pralsetinib (BLU-667) in Patients With Unresectable or Metastatic NSCLC or MTC
- Status
- APPROVED_FOR_MARKETING
- Phase
- N/A
Study of TPX-0046, A RET/SRC Inhibitor in Adult Subjects With Advanced Solid Tumors Harboring RET Fusions or Mutations
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
Expanded Access for the Treatment of Cancers With Rearranged During Transfection (RET) Activation
- Status
- APPROVED_FOR_MARKETING
- Phase
- N/A
A Study of Oral LOXO-292 (Selpercatinib) in Pediatric Participants With Advanced Solid or Primary Central Nervous System (CNS) Tumors
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1/PHASE2